Drug intelligence / Profile preview

AL0206st

Development stage: Unknown
Lead developer: Allergopharma
Modality: Recombinant Proteins and Enzymes
Administration: Sublingual

Overview

AL0206st is a sublingual allergen immunotherapy (SLIT) developed by Allergopharma for the treatment of allergic rhinoconjunctivitis. It is a biologic product composed of a solution of birch pollen allergen extract (*Betula verrucosa*), primarily targeting the major allergen Bet v 1. Unlike symptomatic treatments, AL0206st is a disease-modifying therapy designed to induce immune tolerance and desensitize patients to birch pollen allergens, thereby mitigating the IgE-mediated allergic response. The product has been investigated in Phase 2 clinical trials to evaluate its safety and tolerability in patients with clinically relevant birch pollen allergy.

Other names: Birch pollen allergen extractSublingual birch pollen extractBetula verrucosa allergen extract

Targets

Bet v 1

Beyond the preview

Go deeper on AL0206st.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL0206st.

Explore the full profile